{"id":210,"date":"2020-10-07T16:31:43","date_gmt":"2020-10-07T16:31:43","guid":{"rendered":"https:\/\/www.joinnbio.com\/?page_id=210"},"modified":"2021-05-25T17:50:34","modified_gmt":"2021-05-25T17:50:34","slug":"developability-assesment","status":"publish","type":"page","link":"https:\/\/www.joinnbio.com\/development-services\/developability-assesment\/","title":{"rendered":"Developability Assessment"},"content":{"rendered":"\n
\n\n
<\/div>\n \"\"\n\n<\/div>\n\n\n
\n\n
\n

\n
fig. 1 \u2014<\/span><\/div>\n JOINN Biologics <\/span>\n <\/h3>\n\n

\n Developability Assessment <\/h2>\n <\/div>\n\n<\/div>\n\n\n

Developability assessment evaluates the drug-like properties of lead candidates at the early stage (i.e. discovery), for the potential of being successfully developed into a stable, manufacturable, safe, and efficacious drug product. It is important to carry out this assessment as early as possible in the pre-clinical stage of development to eliminate candidates that do not present a favorable developability profile. This will minimize the risks of costly late-stage failures and avoid potential issues that may occur during the clinical application of a biotherapeutic.<\/p>\n\n\n\n

At JOINN Biologics, a panel of small-scale, fast, and predictive tests are used to evaluate therapeutic antibodies\u2019 developability. The developability evaluation comprises in silico analysis as well as a series of in vitro assays for the drug candidates, so to provide information about the integrity, purity, aggregation, thermostability, charge heterogeneity, glycosylation, poly-reactivity, potency, stability over low pH and accelerated storage conditions, and potential PKPD profile.<\/p>\n\n\n\n

\n